-
Mashup Score: 21What Do Recent Clinical Trials Reveal About Biomarkers for Adjuvant Treatment in Localized RCC, and What’s Still Missing? - 2 month(s) ago
Among patients with high-risk localized renal cell carcinoma, recurrence rates range from 40% to 50% after partial or radical nephrectomy, establishing a critical need for predictive biomarkers to guide adjuvant approaches.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 2Updated Guidelines for Pleural Mesothelioma Highlight New Treatments and Germline Testing - 2 month(s) ago
Updated ASCO guidelines for the treatment of pleural mesothelioma emphasize a reduced role for surgery, new immunotherapy options, and universal germline testing.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
Read in-depth coverage about this new guideline from #ASCODailyNews, featuring interviews with Expert Panel co-chairs Dr. Hedy Kindler of @UChicagoMed and Dr. Raffit Hassan of @theNCI: https://t.co/lXUeggqaEQ
-
-
Mashup Score: 16What Do Recent Clinical Trials Reveal About Biomarkers for Adjuvant Treatment in Localized RCC, and What’s Still Missing? - 2 month(s) ago
Among patients with high-risk localized renal cell carcinoma, recurrence rates range from 40% to 50% after partial or radical nephrectomy, establishing a critical need for predictive biomarkers to guide adjuvant approaches.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Nice piece by @monda_steven and team in #ASCODailyNews: What Do Recent Clinical Trials Reveal About Biomarkers for Adjuvant Treatment in Localized RCC, and What’s Still Missing? https://t.co/ceYSN3LTU9 @ASCO @UMichUrology @theusinghal @wandering_gu
-
-
Mashup Score: 4The AI-Empowered Oncologist: A Look Back at ASCO24 Research to Improve Clinical Use - 3 month(s) ago
The use of artificial intelligence (AI) was a central theme at the 2024 ASCO Annual Meeting, including many tools, such as large language models, clinical trial matching, and image assessment, that are currently in use. However, the use of AI in oncology is in its infancy, and caution is needed given current data set limitations and the risk of amplifying existing disparities.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
The AI-Empowered Oncologist: A Look Back at ASCO24 Research to Improve Clinical Use https://t.co/OAaaBJTubU
-
-
Mashup Score: 5ASCO Issues Systemic Therapy Guideline for Stage I-III Anal Cancer - 3 month(s) ago
A new ASCO guideline provides recommendations on the use of systemic therapy for patients with stage I to III anal squamous cell carcinoma, informed by 2 phase 3 randomized controlled trials, RTOG 98-11 and ACT II, as well as retrospective and prospective cohort studies. However, there remains a growing need in the face of rising mortality and incidence for further research into systemic therapy options for this disease state.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
For more on this new guideline, read an in-depth analysis from #ASCODailyNews featuring insights from Expert Panel co-chair @VanMorrisMD of @MDAndersonNews: https://t.co/1bHQMYkWxp https://t.co/2ygpyY2Lv0
-
-
Mashup Score: 9Podcast: What Challenges Will Oncologists Face in 2025? - 3 month(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrYukselUrun: What Challenges Will Oncologists Face in 2025? @ASCO @n8pennell https://t.co/UqviZEUCag https://t.co/K1AuaLOAcR
-
-
Mashup Score: 9Podcast: What Challenges Will Oncologists Face in 2025? - 3 month(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
RT @DrYukselUrun: What Challenges Will Oncologists Face in 2025? @ASCO @n8pennell https://t.co/UqviZEUCag https://t.co/K1AuaLOAcR
-
-
Mashup Score: 5Podcast: What Challenges Will Oncologists Face in 2025? - 3 month(s) ago
Dr. Nathan Pennell and Dr. John Sweetenham discuss the evolving landscape of oncology in 2025 and the challenges oncologists will be facing, including the impact of Medicare drug price negotiations, ongoing drug shortages, and the promising role of AI and telehealth in improving patient outcomes and access to clinical trials.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Oncologists2Tweet-
Interesting Tallis and thoughts from Nathan Pennell and Sweeteham @n8pennell Podcast: What Challenges Will Oncologists Face in 2025? https://t.co/01gVKi69Hn
-
-
Mashup Score: 2Isatuximab + RVd Improves MRD Negativity, PFS in Patients With Transplant-Eligible, Newly Diagnosed Multiple Myeloma - 3 month(s) ago
Isatuximab is approved to treat disease in patients who are transplant ineligible with newly diagnosed multiple myeloma (MM), but results from a new study show that, when added to another chemotherapy combination, there are also benefits for patients with transplant-eligible, newly diagnosed MM, regardless of subsequent maintenance therapy
Source: dailynews.ascopubs.orgCategories: General Medicine News, Partners & KOLsTweet-
#ASH24 news: GMMG-HD7 trial showed 66.2% of pts w/ transplant-eligible, newly diagnosed #MultipleMyeloma receiving Isa-RVd achieved MRD negativity posttransplant compared w/ 47.7% on RVd alone: https://t.co/PSD2bg2IcV @JCO_ASCO @ASH_hematology @EliasKarlMai #ASCODailyNews #mmsm https://t.co/tz9c2zv702
-
-
Mashup Score: 66
Considerations for a multidisciplinary discussion about treatment for patients with lymph node involvement from MIBC are multifold, including radical cystectomy versus bladder preservation, novel neoadjuvant therapies, and side effect management. However, recent and ongoing clinical trials have provided potential new options for this patient population.
Source: dailynews.ascopubs.orgCategories: General Medicine News, Hem/OncsTweet-
Bladder Preservation vs Radical Cystectomy in Locally Advanced Muscle-Invasive Bladder Cancer: Selecting Treatment for Patients in an Evolving Therapy Landscape @ASCO https://t.co/vRLCrbfbev
-
Nice piece by @monda_steven and team in #ASCODailyNews: What Do Recent Clinical Trials Reveal About Biomarkers for Adjuvant Treatment in Localized RCC, and What’s Still Missing? https://t.co/ceYSN3LTU9 @ASCO @UMichUrology @theusinghal @wandering_gu